Hans E Johnsen
Overview
Explore the profile of Hans E Johnsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
2983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laursen M, Reinholdt L, Schonherz A, Due H, Jespersen D, Grubach L, et al.
Oncotarget
. 2019 Feb;
10(7):717-731.
PMID: 30774774
Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are...
2.
Jafari A, Isa A, Chen L, Ditzel N, Zaher W, Harkness L, et al.
Stem Cells
. 2018 Nov;
37(3):407-416.
PMID: 30485583
Understanding the mechanisms regulating recruitment of human skeletal (stromal or mesenchymal) stem cells (hMSC) to sites of tissue injury is a prerequisite for their successful use in cell replacement therapy....
3.
Ovlisen A, Oest A, Bendtsen M, Baech J, Johansen P, Lynggaard L, et al.
Blood Adv
. 2018 Mar;
2(5):559-564.
PMID: 29523528
Stringent complete remission (sCR) of acute myeloid leukemia is defined as normal hematopoiesis after therapy. Less sCR, including non-sCR, was introduced as insufficient blood platelet, neutrophil, or erythrocyte recovery. These...
4.
Rawstron A, Kreuzer K, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al.
Cytometry B Clin Cytom
. 2017 Oct;
94(1):121-128.
PMID: 29024461
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of...
5.
Svane I, Homburg K, Kamby C, Nielsen D, Roer O, Sliffsgaard D, et al.
Acta Oncol
. 2017 Aug;
41(7-8):675-683.
PMID: 28758869
From 1996 to 2000, high-dose chemotherapy with haematopoietic stem-cell support was used as an adjuvant treatment strategy for management of primary high-risk breast cancer patients with more than five positive...
6.
Bech R, Nielsen K, Larsen T, Bentzen H, Lynggaard L, Do T, et al.
Br J Haematol
. 2017 May;
182(2):297-301.
PMID: 28542714
No abstract available.
7.
El-Galaly T, Villa D, Michaelsen T, Hutchings M, Mikhaeel N, Savage K, et al.
Eur J Cancer
. 2017 Feb;
75:195-203.
PMID: 28237865
Purpose: Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed...
8.
El-Galaly T, Cheah C, Hutchings M, Mikhaeel N, Savage K, Sehn L, et al.
Br J Haematol
. 2016 Sep;
175(5):876-883.
PMID: 27681999
Involvement of the internal female reproductive organs by diffuse large B-cell lymphoma (DLBCL) is uncommon, and there are sparse data describing the outcomes of such cases. In total, 678 female...
9.
Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P, et al.
Lancet Oncol
. 2016 Aug;
17(8):e328-e346.
PMID: 27511158
Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of...
10.
Green T, Jensen A, Holst R, Falgreen S, Bogsted M, de Stricker K, et al.
Br J Haematol
. 2016 May;
174(6):876-86.
PMID: 27196819
We present a multiplex analysis for genes known to have prognostic value in an attempt to design a clinically useful classification model in patients with diffuse large B-cell lymphoma (DLBCL)....